Generic Fabhalta Availability
Last updated on Apr 10, 2024.
Fabhalta is a brand name of iptacopan, approved by the FDA in the following formulation(s):
FABHALTA (iptacopan hydrochloride - capsule;oral)
-
Manufacturer: NOVARTIS
Approval date: December 5, 2023
Strength(s): EQ 200MG BASE [RLD]
Has a generic version of Fabhalta been approved?
No. There is currently no therapeutically equivalent version of Fabhalta available in the United States.
Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Fabhalta. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.
See also: Generic Drug FAQ.
Related patents
Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.
-
Patent 11,603,363
Patent expiration dates:
- May 25, 2041✓✓
- May 25, 2041
-
Piperidinyl-indole derivatives complement factor B inhibitors and uses thereof
Patent 9,682,968
Issued: June 20, 2017
Inventor(s): Adams Christopher Michael & Capparelli Michael Paul & Ehara Takeru & Karki Rajeshri Ganesh & Mainolfi Nello & Zhang Chun
Assignee(s): Novartis AGThe present invention provides a compound of formula I: (I) a method for manufacturing the compounds of the invention, and its therapeutic uses as inhibitors of the complement alternative pathway, in particular of Factor B. The present invention further provides a combination of pharmacologically active agents and a pharmaceutical composition.
Patent expiration dates:
- July 14, 2034✓✓
- July 14, 2034
Related exclusivities
Exclusivity is exclusive marketing rights granted by the FDA upon approval of a drug and can run concurrently with a patent or not. Exclusivity is a statutory provision and is granted to an NDA applicant if statutory requirements are met.
Exclusivity expiration dates:
- December 5, 2028 - NEW CHEMICAL ENTITY
- December 5, 2030 - TREATMENT OF ADULTS WITH PAROXYSMAL NOCTURNAL HEMOGLOBINURIA (PNH)
More about Fabhalta (iptacopan)
- Check interactions
- Compare alternatives
- Pricing & coupons
- Drug images
- Side effects
- Dosage information
- During pregnancy
- FDA approval history
- Drug class: selective immunosuppressants
- En español
Patient resources
Professional resources
Related treatment guides
Glossary
Term | Definition |
---|---|
Drug Patent | A drug patent is assigned by the U.S. Patent and Trademark Office and assigns exclusive legal right to the patent holder to protect the proprietary chemical formulation. The patent assigns exclusive legal right to the inventor or patent holder, and may include entities such as the drug brand name, trademark, product dosage form, ingredient formulation, or manufacturing process A patent usually expires 20 years from the date of filing, but can be variable based on many factors, including development of new formulations of the original chemical, and patent infringement litigation. |
Drug Exclusivity | Exclusivity is the sole marketing rights granted by the FDA to a manufacturer upon the approval of a drug and may run simultaneously with a patent. Exclusivity periods can run from 180 days to seven years depending upon the circumstance of the exclusivity grant. |
RLD | A Reference Listed Drug (RLD) is an approved drug product to which new generic versions are compared to show that they are bioequivalent. A drug company seeking approval to market a generic equivalent must refer to the Reference Listed Drug in its Abbreviated New Drug Application (ANDA). By designating a single reference listed drug as the standard to which all generic versions must be shown to be bioequivalent, FDA hopes to avoid possible significant variations among generic drugs and their brand name counterpart. |
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.